TickerSpark Feed

AXSM Coverage

Every TickerSpark article mentioning AXSM — research reports, earnings, trending movements, and macro context.

2 articles

Axsome Therapeutics (AXSM): AUVELITY Drives a Premium Growth Story

Axsome has evolved into a commercial CNS growth story, led by AUVELITY’s rapid prescription gains and a newly expanded Alzheimer’s agitation opportunity. The stock looks attractive on execution, but valuation and ongoing losses keep it from being a low-risk idea.

May 4, 2026·21 min read

Healthcare Biotechnology Biotech

Trending StockAXSM

Axsome Therapeutics, Inc. (AXSM) climbs on FDA win

Axsome Therapeutics, Inc. (AXSM) climbs after an FDA approval expanded AUVELITY into Alzheimer’s disease agitation, while Q1 2026 revenue jumped 57% year over year. Heavy volume, new highs, and higher analyst targets underscore the market’s growing confidence in Axsome’s commercial momentum.

May 4, 2026·6 min read

Want a deeper dive on AXSM?

Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.

Generate AXSM Report